The drug, known scientifically as ticagrelor, was approved by the FDA in 2011 despite widespread pushback from scientists over concerns about its trial results. Since then, a number of studies ...

Nevertheless, the new sub-analysis could provide a significant boost for Brilinta, as the data suggest treating patients for longer with the drug can prevent more from suffering a second ...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.

An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the ...